Literature DB >> 21297466

Dyslipidemia and lipid management in HIV-infected patients.

Janet Lo1.   

Abstract

PURPOSE OF REVIEW: Dyslipidemia is highly prevalent among patients living with chronic HIV infection and may confer increased risk of cardiovascular disease in this patient population. This review summarizes recent data investigating lipid abnormalities and its management in HIV-infected patients. RECENT
FINDINGS: Studies in the last year have evaluated the effects of various lipid-lowering therapies not previously investigated in the HIV patient population. Rosuvastatin is a potent statin that appears to be well tolerated and effective in HIV-infected patients with hypercholesterolemia.
SUMMARY: Dyslipidemia is common in HIV-infected individuals. Medical therapy of lipid disorders needs to take potential drug-drug interactions of lipid-lowering medications and antiretroviral agents into consideration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21297466      PMCID: PMC3154840          DOI: 10.1097/MED.0b013e328344556e

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  28 in total

1.  Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.

Authors:  D Périard; A Telenti; P Sudre; J J Cheseaux; P Halfon; M J Reymond; S M Marcovina; M P Glauser; P Nicod; R Darioli; V Mooser
Journal:  Circulation       Date:  1999-08-17       Impact factor: 29.690

Review 2.  Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.

Authors:  Michael P Dubé; James H Stein; Judith A Aberg; Carl J Fichtenbaum; John G Gerber; Karen T Tashima; W Keith Henry; Judith S Currier; Dennis Sprecher; Marshall J Glesby
Journal:  Clin Infect Dis       Date:  2003-08-15       Impact factor: 9.079

3.  Drug-drug interactions between raltegravir and pravastatin in healthy volunteers.

Authors:  Matthijs van Luin; Angela Colbers; Eleonora W J van Ewijk-Beneken Kolmer; Corrien P W G M Verweij-van Wissen; Bas Schouwenberg; Arjen Hoitsma; Hugo G da Silva; David M Burger
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

4.  Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.

Authors:  C Hadigan; J B Meigs; C Corcoran; P Rietschel; S Piecuch; N Basgoz; B Davis; P Sax; T Stanley; P W Wilson; R B D'Agostino; S Grinspoon
Journal:  Clin Infect Dis       Date:  2000-12-15       Impact factor: 9.079

5.  Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

Authors:  Carl J Fichtenbaum; John G Gerber; Susan L Rosenkranz; Yoninah Segal; Judith A Aberg; Terrence Blaschke; Beverly Alston; Fang Fang; Bradley Kosel; Francesca Aweeka
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

Review 6.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

7.  Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population.

Authors:  Marianne Savès; Geneviève Chêne; Pierre Ducimetière; Catherine Leport; Gwenaël Le Moal; Philippe Amouyel; Dominique Arveiler; Jean-Bernard Ruidavets; Jacques Reynes; Annie Bingham; François Raffi
Journal:  Clin Infect Dis       Date:  2003-07-07       Impact factor: 9.079

8.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

Authors:  C Grunfeld; M Pang; W Doerrler; J K Shigenaga; P Jensen; K R Feingold
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

9.  Impact of HIV infection and HAART on serum lipids in men.

Authors:  Sharon A Riddler; Ellen Smit; Stephen R Cole; Rui Li; Joan S Chmiel; Adrian Dobs; Frank Palella; Barbara Visscher; Rhobert Evans; Lawrence A Kingsley
Journal:  JAMA       Date:  2003-06-11       Impact factor: 56.272

10.  Combination antiretroviral therapy and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa M El-Sadr; Peter Reiss; Rodolphe Thiébaut; Linda Morfeldt; Stephane De Wit; Christian Pradier; Gonzalo Calvo; Matthew G Law; Ole Kirk; Andrew N Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

View more
  21 in total

1.  HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons.

Authors:  Chun Chao; Lanfang Xu; Donald I Abrams; William J Towner; Michael A Horberg; Wendy A Leyden; Michael J Silverberg
Journal:  AIDS       Date:  2011-09-10       Impact factor: 4.177

2.  Differences by HIV serostatus in coronary artery disease severity and likelihood of percutaneous coronary intervention following stress testing.

Authors:  Matthew J Feinstein; Brian Poole; Pedro Engel Gonzalez; Anna E Pawlowski; Daniel Schneider; Tim S Provias; Frank J Palella; Chad J Achenbach; Donald M Lloyd-Jones
Journal:  J Nucl Cardiol       Date:  2016-10-13       Impact factor: 5.952

Review 3.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

4.  Predicting and preventing cardiovascular disease in HIV-infected patients.

Authors:  Wendy S Post
Journal:  Top Antivir Med       Date:  2011-12

5.  Spectrum of Dyslipidemias in Treatment-Naïve Human Immunodeficiency Virus-Infected Patients Presenting to an HIV Clinic of a Tertiary Care Hospital.

Authors:  Sadaf Iqbal; Sadia Salman; Mehwish Akhtar; Amanullah Bhalli; Javeid Iqbal; Ismat Ullah
Journal:  Cureus       Date:  2022-02-07

Review 6.  Metabolic Consequences of Antiretroviral Therapy.

Authors:  Caroline E Diggins; Samuel C Russo; Janet Lo
Journal:  Curr HIV/AIDS Rep       Date:  2022-03-17       Impact factor: 5.071

Review 7.  Astrocyte elevated gene-1 (AEG-1) and the A(E)Ging HIV/AIDS-HAND.

Authors:  Neha Vartak-Sharma; Shruthi Nooka; Anuja Ghorpade
Journal:  Prog Neurobiol       Date:  2016-04-14       Impact factor: 11.685

8.  HIV-1 Vpr enhances PPARβ/δ-mediated transcription, increases PDK4 expression, and reduces PDC activity.

Authors:  Shashi Shrivastav; Liyan Zhang; Koji Okamoto; Hewang Lee; Claudia Lagranha; Yoshifusa Abe; Ashok Balasubramanyam; Gary D Lopaschuk; Tomoshige Kino; Jeffrey B Kopp
Journal:  Mol Endocrinol       Date:  2013-07-10

9.  The Relationship between HIV Duration, Insulin Resistance and Diabetes Risk.

Authors:  Eduard Tiozzo; Allan Rodriguez; Janet Konefal; Gary J Farkas; Jennifer L Maher; John E Lewis
Journal:  Int J Environ Res Public Health       Date:  2021-04-08       Impact factor: 3.390

Review 10.  Viral Bad News Sent by EVAIL.

Authors:  Matthias Clauss; Sarvesh Chelvanambi; Christine Cook; Rabab ElMergawy; Navneet Dhillon
Journal:  Viruses       Date:  2021-06-18       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.